Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Shares of Sarepta Therapeutics (SRPT) are under pressure on Tuesday after the company shared a safety update related to its Elevidys, the only ...
Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, ...
Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare musc ...
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
The young man died of acute liver injury, a known side effect, Sarepta said in a statement. But the company said the ...
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Sarepta Therapeutics said on Tuesday a 16-year-old boy has died due to acute liver failure, months after he received the company's U.S-approved gene therapy for a rare muscular dystrophy. The patient ...
Shares of Sarepta Therapeutics fell after the company said a patient with Duchenne muscular dystrophy died of liver failure after using its Elevidys treatment. The stock opened the market down 22% at ...